Federal Grant Award Summary

Northeast Ohio Medical University (Neomed) received a $336,355 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective April 1, 2026 through January 31, 2031. The award funds a five-year research initiative investigating the impact of sex chromosomes and hormones on drug metabolism and transport. The research employs pharmacokinetics and pharmaco-omics approaches—including pharmacogenomics, proteomics, and metabolomics—to identify genetic and non-genetic factors influencing drug disposition and response, with the ultimate goal of advancing precision medicine and optimizing drug efficacy and safety.

The project addresses critical knowledge gaps regarding sex-based differences in drug-metabolizing enzymes and transporters, which contribute to women experiencing nearly twice the rate of adverse drug reactions as men. Using the Four Core Genotype mouse model, human tissue analyses, and integrated pharmaco-omics tools, the research will dissect the independent and interactive roles of sex chromosomes and hormones in regulating drug metabolism. Through biomarker discovery, mechanistic exploration, and predictive modeling, this work is expected to generate evidence-based insights to reduce treatment failures and toxicity risk, particularly for female patients and those experiencing hormonal fluctuations such as menopause.